1. Investment Opportunity and
Company Overview
July 2018

2. Clinical Stage Pharmaceutical Company
Targeted Anti-Cancer Drugs
1st Drug Candidate in 2nd phase of Human Clinical
Trials at Mayo Clinic, and effective in 2 of 2 patients.
2nd Drug Candidate approved by FDA to begin
clinical trials

3. IGF-MTX
Lead drug candidate. Chemotherapy drug methotrexate (MTX) attached to insulin-like growth factor (IGF).
Targets IGF receptor overexpressed on cancer cells.

4. IGF-MTX targeting and mechanism of action

5. IGF-MTX
In mouse study with prostate cancer, IGF-MTX was more effective than free MTX even at 13-fold lower dose of IGF-MTX

6. IGF-MTX Phase 1 Human Clinical Trial Results
ZERO chemo side effect decrease in blood counts
Evidence of efficacy at 0.2 microEq/kg, about 12-fold lower than the standard dose of methotrexate.
Efficacy in 3 solid tumor types, and one lymphoma patient now cancer-free.

7. Mayo Clinic Trial in a Blood Cancer
Myelodysplastic syndrome (MDS)
5,000 to 10,000 cases per year.
No very effective treatment. Life expectancy 24 months.
High expression of IGF receptor in MDS cells.
IGF-MTX is effective against MDS cells in vitro at low dose.
MDS patients cannot tolerate normal chemo because of side effects.
But we and the Mayo doctors think they will be able to tolerate IGF-MTX because of the lack of side effects, and that it is likely to be effective.
Now effective in 2 of 2 patients with life expectancy of 3-6 months at start of treatment.
But we need investor funding to continue this clinical trial.

8. IGF-MTX market size
Market size $250 million annually in U.S. alone in MDS alone.
5,000-10,000 cases per year in U.S. of MDS.
$50,000 estimated per course of treatment.

9. CPE-54, second drug candidate
We are approved by FDA to begin clinical trials, pending funding.
Late stage ovarian cancer.
Targeted drug, but acts by entirely different mechanism from IGF-MTX, so its success is independent of IGF-MTX.

10. Other pipeline drugs EGF-X
Other conjugates to IGF and EGF (epidermal growth factor) to target cancer with reduced side effects and greater efficacy.

11. Intellectual Property
IGF-MTX.
5 issued U.S. Patents provide exclusivity to Other pending applications extend that to Issued or pending patents also in Canada, Japan, Europe, India, Australia. Newly filed PCT patent application will be filed in China also.
CPE-54
2 issued U.S. Patents provide exclusivity to 2025.
Applications to be filed in 2018 will provide exclusivity to 2039.

12. Management Hugh McTavish, Ph.D., J.D. CEO and founder.
Biochemist, inventor of most of the company’s technology, and patent attorney. Also former cancer patient.
Arkadiusz Dudek, M.D., Ph.D. Chief Medical Officer.
Oncologist and Director of Oncology clinical trials at Health Partners, St. Paul, MN. Former professor at University of Minnesota and University of Illinois Chicago Medical Schools.
Ronald Way. Board member.
Former U.S. Senate staffer and journalist. Current board member for several medical device and pharmaceutical companies.
Kathleen Littrell. Senior Director Clinical Operations.
Has more than 20 years experience in all phases of clinical trials.

13. Capitalization
IGF Oncology, LLC is a Delaware limited liability company.
3,006,875 shares outstanding.

14. Contact
Hugh McTavish, Ph.D., J.D